Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Grünenthal

Tracked across 3 events · 28 articles · First seen Jun 29, 2026 · Last active Jul 16, 2026

Sentiment
32
Attention
4
Events
3
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 70
Tech
Impact: Grünenthal successfully completed a Phase I trial for its NOP agonist, demonstrating its safety and tolerability. This positive development allows the company to advance the compound to Phase II trials, potentially leading to a new pain treatment option and enhancing Grünenthal's market position in pain management.
Jun 29, 2026 · 9 articles
2 15
Regulatory
Impact: Grünenthal received FDA designations for its investigational drug tegacorat, a positive regulatory milestone that may enhance its pipeline value and future revenue prospects.
Jul 08, 2026 · 10 articles
2 10
Business
Impact: Grünenthal is the main actor, joining CNATM to enhance its oligonucleotide capabilities for pain and neurological diseases. This strengthens its R&D pipeline in genetic medicine.
Jul 16, 2026 · 9 articles
Uli Brödl Grünenthal
Uli Brödl chief scientific officer Grünenthal Uli Brödl is the Chief Scientific Officer and a member of the Corporate Executiv
ERGEN INTELLIGENCE
Track Grünenthal live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.